Overview

A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer

Status:
Completed

Trial end date:
2018-03-02

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety and efficacy of HKI-272 (neratinib) in combination with trastuzumab in patients with advanced breast cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Puma Biotechnology, Inc.

Treatments:

Trastuzumab